How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies

  • Pusceddu S
  • De Braud F
  • Russo G
  • et al.
N/ACitations
Citations of this article
12Readers
Mendeley users who have this article in their library.

Abstract

In the last five years, everolimus has demonstrated efficacy in the treatment of neuroendocrine tumors (NETs) of different origins; its efficacy and safety were explored in the RADIANT trials, the last of which (RADIANT-4) has been recently published (December 2015). Overall, evidence collected from the RADIANT studies holds promise to change clinical practice for the treatment of NETs.In this paper, we comment on the role of everolimus within the therapeutic algorithm for NETs treatment, based on the systematic analysis of the RADIANT trials and our experience.

Cite

CITATION STYLE

APA

Pusceddu, S., De Braud, F., Russo, G. L., Concas, L., Femia, D., Vernieri, C., … Buzzoni, R. (2016). How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies. Oncotarget, 7(28). https://doi.org/10.18632/oncotarget.8601

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free